An observational study in Acute Kidney Injury and Renal Insufficiency, sponsored by Baylor Research Institute. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by Baylor Research Institute · Observational
To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.
Specific Aims:
To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
Measurements:
CI-AKI will be assessed by several methods during the period from angiography to cardiac surgery:
CSA-AKI will be defined by several methods:
Baseline eGFR will be calculated using the CKD-EPI formula
GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black]
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.
This study's enrollment of 965 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Baylor Research Institute is the lead sponsor of 219 studies on the registry; 49 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.
Counted across the registry records on this site, refreshed daily.
Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one baseline and postoperative serum creatinine (mg/dl).
Exclusion Criteria:
coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
Contrast-induced acute kidney injury
KDIGO definition
Time frame: 7 days
Cardiac surgery associated acute kidney injury
KDIGO definition
Time frame: 7 days
Major adverse renal and cardiac events
Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
Time frame: 30 days
Renal replacement therapy
at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
Time frame: 30 days
Myocardial Infarction
Myocardial infarction as defined by STS
Time frame: 30 days
Stroke
Stroke as defined by STS
Time frame: 30 days
Heart failure
Heart failure
Time frame: 30 days
Hospitalization for renal reasons
Hospitalization for renal reasons
Time frame: 30 days
Hospitalization for cardiac reasons
Hospitalization for cardiac reaons
Time frame: 30 days
Death
Death
Time frame: 30 days
All-cause hospitalization
All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
Time frame: 30 days
Days out of the hospital and alive
Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
Time frame: 1 year
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baylor Research Institute